Lantheus Holdings announced a strategic collaboration with SonoThera. Under the agreement, Lantheus’ microbubbles will be used in combination with SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments. SonoThera plans to combine its nonviral vector gene therapy delivery technology with Lantheus’ microbubble in several applications. Microbubble ultrasound enhancing agents have the potential to dramatically improve gene therapy treatments by enhancing the delivery of genetic payloads to tissue. The physical response of microbubbles in an ultrasound field can transiently disrupt biological barriers such as the vasculature and cell membranes, enhancing genetic payload permeability into tissue.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LNTH:
- Lantheus announces pricing of offering of $500M convertible senior notes
- Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
- Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
- Lantheus announces proposed offering of $500M convertible senior notes
- Lantheus appoints Amanda Morgan SVP, commercial
